The Estée Lauder Companies Makes Minority Investment in 111SKIN

The Estée Lauder Companies (ELC) has announced a minority investment in 111Skin, the British skincare brand founded by plastic surgeon Dr. Yannis Alexandrides and Eva Alexandrides.

Founded in 2012, 111Skin originated as a clinical solution to accelerate post-surgical healing. The brand’s identity is anchored in its proprietary NAC Y2 complex, a reparative formula that has since evolved from Harley Street recovery rooms into a rich portfolio of over 30 products.

“We are thrilled to be partnering with The Estée Lauder Companies and to unlock an exciting new chapter for 111Skin,” said Dr. Yannis Alexandrides and Eva Alexandrides. “We look forward to building on our momentum and driving future growth together,” added 111Skin CEO Vanessa Goddevrind.

Strategically, the investment allows ELC to tap into a brand with a highly sophisticated global footprint. In 2025, North America accounted for approximately 40% of 111Skin’s sales, complemented by established operations in China, Europe, and the Asia-Pacific region. The brand’s retail strategy is equally robust, balancing high-end physical distribution, including Harrods, Bluemercury, and Aman resorts, with a direct-to-consumer business that drives roughly 20% of its total revenue.

“Skin care is entering a new phase, shaped by the convergence of procedures, longevity and beauty, as consumers increasingly seek products that deliver visible, treatment-inspired results,” said Stéphane de La Faverie, President and CEO of ELC. “111Skin exemplifies this shift, translating Dr. Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skin care inspired by in-clinic treatments and built on clinical insight, next-generation actives, powerful formulas and proven efficacy. This investment, grounded in consumer-centricity and transformative innovation, reflects our Beauty Reimagined vision and underscores the significant opportunity we see to support the brand’s continued growth.”

Dr. Alexandrides will continue to lead the brand alongside the current management team, ensuring that the clinical authority of the brand remains intact. The financial terms of the deal remain undisclosed.